CAI
HealthcareCaris Life Sciences, Inc. · Biotechnology · $4B
What is Caris Life Sciences, Inc.?
Caris Life Sciences is an AI-driven TechBio company focused on molecular profiling for cancer care. Founded in 2008 and headquartered in Irving, Texas, it serves patients, oncologists, and biopharma partners across the United States and internationally.
Caris Life Sciences generates revenue through two primary channels: molecular profiling services sold to oncologists and health systems, and research and development services sold to biopharmaceutical companies. Its tissue-based and blood-based profiling solutions analyze a tumor's molecular makeup to guide treatment decisions. On the pharma side, the company provides laboratory, data, and research services that help drug developers identify patient populations and accelerate clinical programs. Machine learning algorithms run throughout the platform, connecting molecular data to clinical outcomes.
Caris Life Sciences was founded in 2008 and is headquartered in Irving, Texas.
- MI Profile — tissue-based molecular profiling for cancer treatment guidance
- Caris Assure — blood-based liquid biopsy profiling solution
- Pharma R&D services including laboratory delivery and strategic data
- AI and machine learning algorithms applied to molecular datasets
Is CAI a Good Stock to Buy?
UQS Score rates CAI as Good overall, reflecting a company with meaningful strengths and some areas that warrant closer scrutiny.
The Growth pillar stands out as the clearest positive signal — Caris is expanding its revenue base at a pace that ranks among the stronger profiles in the healthcare sector. The Risk pillar also reads as Good, suggesting the company's financial structure and operational profile carry a manageable level of downside exposure relative to peers.
The Moat pillar registers as Weak, indicating that durable competitive advantages are not yet firmly established. Valuation is flagged as Elevated, meaning the market is already pricing in a significant portion of the growth story.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does CAI pay dividends?
No — Caris Life Sciences, Inc. does not currently pay a dividend.
Caris Life Sciences does not currently pay a dividend. As a growth-stage TechBio company, it reinvests available capital into expanding its molecular profiling platform, building out its AI capabilities, and growing its pharma services business. Income-focused investors should be aware that no cash distribution is expected in the near term.
When does CAI report earnings?
Caris Life Sciences reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
The company's Growth pillar signals that top-line expansion has been a defining characteristic of recent operating periods. As a relatively recent public entrant, its quarterly results are closely watched for evidence that molecular profiling adoption is accelerating and that pharma partnerships are scaling.
For the most recent quarter's results and guidance commentary, visit Caris Life Sciences' investor relations page directly.
CAI Price History
-22.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
CAI Long-term Outlook
The Strong Growth pillar points to a business that is expanding meaningfully, driven by rising demand for precision oncology tools and a growing roster of biopharma partners. The Good Risk profile suggests the company is managing its balance sheet and operational risks with reasonable discipline for a growth-stage healthcare name. However, the Elevated Valuation pillar signals that the current share price already reflects a great deal of optimism, leaving limited room for execution missteps.
Growth drivers
- Accelerating adoption of molecular profiling in oncology treatment decisions
- Expanding pharma R&D services revenue from biopharma partnerships
- AI-driven platform differentiation attracting new clinical and commercial customers
Key risks
- Weak Moat pillar suggests competitors could erode market share over time
- Elevated Valuation leaves the stock sensitive to any growth disappointments
- Reimbursement and regulatory dynamics in molecular diagnostics remain fluid
CAI vs Peers
Caris Life Sciences operates in a competitive healthcare landscape alongside companies pursuing distinct strategies in therapeutics and diagnostics.
PTC focuses on rare disease drug development rather than molecular profiling, making it a therapeutics-oriented peer rather than a direct diagnostics competitor.
Immunovant is a clinical-stage immunology company developing antibody therapies, operating in a different segment of the healthcare value chain than Caris.
Celcuity combines cellular analysis with targeted oncology drug development, sharing some overlap with Caris in the precision cancer space.
Frequently Asked Questions
What does Caris Life Sciences do?
Caris Life Sciences provides molecular profiling services that analyze the genetic and molecular characteristics of tumors to help oncologists select appropriate cancer treatments. It also sells research and data services to biopharmaceutical companies. The company applies machine learning algorithms to its molecular datasets to generate clinical insights.
Does CAI pay dividends?
No, Caris Life Sciences does not pay a dividend. The company is in a growth phase and directs its capital toward expanding its molecular profiling platform and AI capabilities rather than returning cash to shareholders.
When does CAI report earnings?
Caris Life Sciences follows a standard quarterly earnings reporting schedule. Specific dates are not covered by our data source, so investors should check the company's investor relations page for the most current schedule and recent results.
Is CAI a good stock to buy?
UQS Score rates CAI as Good overall. The Growth pillar is Strong and the Risk pillar reads as Good, which are positive signals. However, the Moat pillar is Weak and Valuation is Elevated, meaning the market has already priced in significant growth. The full pillar breakdown is available to Pro members.
Is CAI overvalued?
The UQS Valuation pillar for CAI is rated Elevated, suggesting the current market price reflects a high degree of growth optimism. Whether that premium is justified depends on how well the company executes on its molecular profiling and pharma services expansion. Investors should weigh this against the Strong Growth signal.
How does CAI compare to its competitors?
Caris competes in a broad healthcare landscape alongside companies like PTC Therapeutics, Immunovant, and Celcuity. Each pursues a different strategy — from rare disease therapeutics to immunology — while Caris is focused squarely on molecular profiling and AI-driven oncology data. The UQS platform scores each company independently for direct comparison.
What is CAI's market cap bracket?
Caris Life Sciences is classified as a mid-cap company. This places it in a segment that often balances growth potential with greater volatility than large-cap peers, and it may receive less institutional coverage than mega-cap healthcare names.
Who founded Caris Life Sciences?
Caris Life Sciences was founded in 2008. For detailed founding history and leadership background, the company's official website and investor relations materials are the most reliable sources.
Is CAI a long-term quality investment?
From a long-term quality perspective, the Strong Growth pillar is encouraging, but the Weak Moat pillar raises questions about whether Caris can sustain a durable competitive advantage over time. Long-term quality investors typically look for both growth and moat strength together. The full UQS analysis helps contextualize where CAI stands on each dimension.
What is the main competitive advantage of Caris Life Sciences?
Caris differentiates through the breadth of its molecular profiling platform — combining tissue-based and blood-based testing with AI-driven analytics — and its dual revenue model serving both clinicians and biopharma companies. However, the UQS Moat pillar currently rates this advantage as Weak, suggesting it is not yet firmly entrenched.
What sector does CAI belong to?
Caris Life Sciences operates in the Healthcare sector, specifically within the molecular diagnostics and TechBio space. It sits at the intersection of oncology diagnostics, data analytics, and pharmaceutical services — a segment that is growing as precision medicine adoption increases.
Is CAI a growth stock or value stock?
Based on its UQS pillar profile, CAI leans firmly toward the growth category. The Growth pillar is rated Strong while the Valuation pillar is Elevated, a combination typical of companies where the market is paying a premium in anticipation of continued rapid expansion rather than current earnings power.
Unlock Full CAI Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar ratings
- ✓Access complete financial metrics and trend data
- ✓Compare CAI against sector peers side by side
- ✓See the full risk and valuation breakdown
- ✓Get the complete analyst-grade quality report
Pro Analysis
CAI — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 23, 2026 | 58.5 | 48.0 | 37.0 | 98.9 | 84.3 | 32.1 | 0.0 |
| May 22, 2026 | 58.5 | 48.0 | 37.0 | 98.9 | 84.3 | 32.0 | 0.0 |
| May 21, 2026 | 58.5 | 48.0 | 37.0 | 98.9 | 84.3 | 32.1 | 0.0 |
| May 20, 2026 | 58.5 | 48.0 | 37.0 | 98.9 | 84.3 | 32.4 | 0.0 |
| May 19, 2026 | 58.5 | 48.0 | 37.0 | 98.9 | 84.3 | 32.3 | -0.2 |
| May 16, 2026 | 58.7 | 48.0 | 37.0 | 98.9 | 84.3 | 33.3 | +0.2 |
| May 15, 2026 | 58.5 | 48.0 | 37.0 | 98.9 | 84.3 | 32.3 | -0.1 |
| May 14, 2026 | 58.6 | 48.0 | 37.0 | 98.9 | 84.3 | 32.9 | +0.2 |
| May 13, 2026 | 58.4 | 48.0 | 37.0 | 98.9 | 84.3 | 31.8 | -0.1 |
| May 12, 2026 | 58.5 | 48.0 | 37.0 | 98.9 | 84.3 | 32.1 | 0.0 |
CAI — Pillar Breakdown
Quality
— 48.0/100 (25%)Caris Life Sciences, Inc. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 98.9/100 (20%)Caris Life Sciences, Inc. is growing rapidly with strong revenue and earnings expansion.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 84.3/100 (15%)Caris Life Sciences, Inc. carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 32.1/100 (15%)Caris Life Sciences, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Inverse of forward P/E — higher yield means cheaper stock.
How many years of FCF the market cap represents.
P/E relative to earnings growth — lower is more attractive.
Enterprise value multiple relative to sector median.
Moat
— 37/100 (25%)Caris Life Sciences, Inc. possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CAI.
Score Composition
Financial Data
More Stock Analysis
How is the CAI UQS Score Calculated?
The UQS (Unified Quality Score) for Caris Life Sciences, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Caris Life Sciences, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Caris Life Sciences, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.